Blood MSI dynamics as a predictive biomarker of immune checkpoint inhibitor therapy efficacy in colorectal cancer (CRC): preliminary results from an observational trial

被引：0
作者：
Byakhova, M. [1 ]
Veselovsky, E. [1 ]
Yudina, V. [1 ]
Kuznetsova, O. [1 ]
Kravchuk, D. [1 ]
Lebedeva, A. [1 ]
Belova, E. [1 ]
Taraskina, A. [1 ]
Grigoreva, T. [1 ]
Kavun, A. [1 ]
Nikulin, V. [1 ]
Mileyko, V. [1 ]
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Ivanov, M. [1 ]
机构：
[1] City Clin Oncol Hosp 1, Novosibirsk, Russia
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
基金：
俄罗斯科学基金会;
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-19-01
引用
收藏
页码：S422 / S422
页数：1
相关论文
共 50 条
  • [41] Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Sawada, Ryo
    Azuma, Koichi
    Goto, Yasuhiro
    Harada, Taishi
    Shiotsu, Shinsuke
    Tamiya, Nobuyo
    Chihara, Yusuke
    Takeda, Takayuki
    Hiranuma, Osamu
    Hasegawa, Isao
    Tanaka, Satomi
    Yoshimura, Akihiro
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kim, Young Hak
    Takayama, Koichi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1699 - 1707
  • [42] The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer Results from the Nordic ACT trial
    Hansen, Torben Frostrup
    Christensen, Rene dePont
    Andersen, Rikke Fredslund
    Spindler, Karen-Lise Garm
    Johnsson, Anders
    Jakobsen, Anders
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (06) : 715 - 720
  • [43] KRAS MUTATION STATUS IS A PREDICTIVE BIOMARKER FOR CETUXIMAB BENEFIT IN THE TREATMENT OF ADVANCED COLORECTAL CANCER - RESULTS FROM NCIC CTG CO.17: A PHASE III TRIAL OF CETUXIMAB VERSUS BEST SUPPORTIVE CARE
    Karapetis, Christos
    Khambata-Ford, Shirin
    Jonker, Derek
    O'Callaghan, Chris
    Tu, Dongsheng
    Vachan, Burcu
    Simes, John
    Langer, Christiane
    Moore, Malcolm
    Zalcberg, John
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [44] SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL
    Levi, F.
    Boige, V.
    Rougier, P.
    Hebbar, M.
    Smith, D.
    Focan, C.
    Guimbaud, R.
    Carvalho, C.
    Bouchahda, M.
    Ducreux, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 194 - 194
  • [45] Novel blood-based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non-small-cell lung cancer: Results from two multicenter, randomized clinical trials
    Yu, Yunfang
    Chen, Yongjian
    Li, Anlin
    Ou, Qiyun
    Li, Qingjian
    Gu, Yang
    Lin, Dagui
    Zhang, Wenda
    Wang, Jingshu
    Tang, Xudong
    Li, Zhihua
    Hu, Hai
    Yao, Herui
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (02):
  • [46] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
    Grohe, Christian
    Wehler, Thomas
    Dechow, Tobias
    Henschke, Sven
    Schuette, Wolfgang
    Dittrich, Ina
    Hammerschmidt, Stefan
    Mueller-Huesmann, Harald
    Schumann, Christian
    Krueger, Stefan
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] A randomized controlled trial to compare laparoscopic surgery with open surgery for symptomatic, non-curable stage IV colorectal cancer (CRC): First efficacy results from Japan clinical oncology group study JCOG1107
    Akagi, T.
    Inomata, M.
    Kanzaka, R.
    Katayama, H.
    Fukuda, H.
    Shiomi, A.
    Ito, M.
    Watanabe, J.
    Murata, K.
    Hirano, Y.
    Shimomura, M.
    Shunsuke, T.
    Hamaguchi, T.
    Kanemitsu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S726 - S726
  • [48] 5-FU/LV + cetuximab plus vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
    Ducreux, M.
    Tabernero, J.
    Grothey, A.
    Arnold, D.
    O'Dwyer, P.
    Perdicchio, M.
    Assaf, Z.
    Das Thakur, M.
    Irahara, N.
    Tahiri, A.
    Schmoll, H.
    Van Cutsem, E.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S221 - S222
  • [49] A randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision (CME) for stage II, III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404.
    Inomata, Masafumi
    Katayama, Hiroshi
    Mizusawa, Junki
    Watanabe, Masahiko
    Sugihara, Kenichi
    Konishi, Fumio
    Yamamoto, Seiichiro
    Saito, Shuji
    Fujii, Shoichi
    Saida, Yoshihisa
    Hasegawa, Hirotoshi
    Etoh, Tsuyoshi
    Moriya, Yoshihiro
    Kitano, Seigo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial
    Browne, Iseult
    Pascual, Javier
    Cutts, Rosalind
    Kingston, Belinda
    Hrebien, Sarah
    Kilburn, Lucy
    Pearson, Alex
    Moretti, Laura
    Wardley, Andrew
    Macpherson, Iain
    Baird, Richard
    Roylance, Rebecca
    Faull, Iris
    Banks, Kimberly C.
    Garcia-Murillas, Isaac
    Bliss, Judith
    Ring, Alistair
    Turner, Nicholas
    CANCER RESEARCH, 2024, 84 (09)
12345